ABSTRACT
Introduction World Health Organization (WHO) updated guidelines for maternal HIV, syphilis and hepatitis B virus (HBV) testing for pregnant women, and advised on using dual HIV/syphilis rapid diagnostic tests (RDTs). We reviewed national testing guidelines to assess political support in alignment with WHO guidance and triple elimination of mother-to-child transmission (MTCT) priorities.
Methods We reviewed national HIV-related guidelines from 46 African countries after 2010, including guidelines on prevention MTCT, HIV testing/self-testing, HIV antiretroviral treatment, and/or HIV pre-exposure prophylaxis. Data was extracted data on recommendations for maternal testing for HIV (frequency and timing), syphilis (any test/test type); and HBV. Testing recommendations for all three infections in the most recent country guidelines were compared to WHO guidelines.
Results Testing policies on HIV, syphilis, or HBV during pregnancy and/or postpartum from 38 (83%) countries were identified; 18 (47%) had policies updated after 2019 and 11 (29%) were high HIV burden. All 38 countries with HIV testing guidelines addressed maternal HIV retesting, while 68% had guidelines recommending syphilis testing (46% of which recommended the dual RDT), and 58% had HBV testing guidelines. Maternal HIV retesting was more frequent than recommended by WHO in 2019 in 9/11 (82%) and 7/27 (26%) of high and low HIV burden countries, respectively. Half of countries had triple elimination of MTCT focused policies, and 10 (26%) had maternal HIV retesting as well as syphilis and/or HBV testing guidance.
Conclusions Half of countries had guidelines to test for all three infections; policy evaluations to measure implementation and impact are needed.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by 2022/1245214-0 PO#202879943.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
E-mail addresses of authors: KL: klist{at}uw.edu
AMW: monroewisea{at}who.int
MB: banksme{at}uw.edu
MBD: barrdichiaram{at}who.int
AC: chettya{at}who.int
MNO: newmanm{at}who.int
OL: lesio{at}who.int
CJ: johnsonc{at}who.int
Data Availability
All data produced in the present study are available upon reasonable request to the authors.